HealthQuill Immunotherapy
Germany’s BioNTech SE will acquire CureVac N.V., which develops therapies based on messenger RNA, for $1.25 billion in an all-stock deal to expand the former’s mRNA-based cancer immunotherapy candidates.
Drugs Health Pharma

BioNTech SE to acquire CureVac for $1.25 billion in all-stock deal

HQ Team June 12, 2025: Germany’s BioNTech SE will acquire CureVac N.V., which develops therapies based on messenger RNA, for $1.25 billion in.

Read More
An investigational therapy from Kite Pharma Inc., a Gilead Sciences company, has reduced tumours in 62% of the patients with a fatal form of brain cancer.
Drugs Health Pharma

Gilead unit’s experimental therapy shrink brain tumours by 62%

HQ Team June 2, 2025: An investigational therapy from Kite Pharma Inc., a Gilead Sciences company, has reduced tumours in 62% of the.

Read More
mrnA cancer vaccine
Drugs Medical

Tailored kidney cancer trial vaccine shows recurrence-free survival

HQ Team  February 6, 2025: A phase I clinical trial has shown that personalized cancer vaccines targeting driver mutations can lead to 100%.

Read More
Alzheimer's
Health Medical

Brain shrinkage from Alzheimer’s therapy is desirable, not harmful: Study

Bharti Jayshankar December 2, 2024: A recent study by University College London (UCL) has revealed that the decrease in brain volume observed in.

Read More
British drugmaker, GSK Plc.’s multiple myeloma drug, Blenrep, reduced the risk of disease progression or death by about 50% when compared to a standard-of-care combination, according to the company.
Drugs Health Medical

New CAR T-cell therapy offers hope for children with aggressive blood cancer

HQ Team October 14, 2024: Children with aggressive blood cancer may soon have access to a new treatment, CAR T-cell therapy, targeting T-cell.

Read More
Merck & Co., announced its trial drug along with a combination of the company’s Keytruda therapy failed to meet the main goal of overall survival in patients previously treated for a type of metastatic colorectal cancer. 
Drugs Health Pharma

Merck’s trial drug combination for colorectal cancer fails main goal

Merck & Co., announced its trial drug along with a combination of the company’s Keytruda therapy failed to meet the main goal of.

Read More
Merck & Co’s combination drug, Keytruda, which treats advanced lung cancer, has been approved by the US drug regulator, the Food and Drug Administration.
Drugs Health Pharma

Merck’s advanced lung cancer drug gets US drug regulator’s nod

Merck & Co’s combination drug, Keytruda, which treats advanced lung cancer, has been approved by the US drug regulator, the Food and Drug.

Read More
mrnA cancer vaccine
Drugs Health Medical

World’s first lung cancer vaccine given to patient in UK as human trials begin

HQ team August 23, 2024: .An mRNA-based lung cancer vaccine is being tested for the first time on patients in the UK. Known.

Read More
Citius Pharmaceuticals, Inc., a US-based biotechnology company, got a green light from the country’s drug regulator for its immunotherapy treatment for a rare form of blood cancer that affects the skin.
Drugs Health Pharma

Citius’s blood cancer drug gets US regulatory body’s clearance 

Citius Pharmaceuticals, Inc., a US-based biotechnology company, got a green light from the country’s drug regulator for its immunotherapy treatment for a rare.

Read More
Merck has stopped an end-stage combination immunotherapy trial for a lung cancer condition, following recommendations of an independent data monitoring committee, which indicated the drug wouldn’t succeed.
Drugs Health Pharma

Merck halts small cell lung cancer immunotherapy drug trial

Merck has stopped an end-stage combination immunotherapy trial for a lung cancer condition, following recommendations of an independent data monitoring committee, which indicated.

Read More